Two parts of a blood panel carry the evidence on RAD 140 blood work: the liver tests and the sex-hormone panel. In the one human trial, in women with advanced breast cancer, many participants showed raised liver enzymes (the aminotransferases released from injured liver tissue) and raised bilirubin, the bile pigment that liver tissue clears from blood.
In the same trial, sex hormone-binding globulin (SHBG, the main carrier protein for testosterone in blood) fell in every participant with a measured value; a published case report from outside the trial describes a severe drug-induced liver injury detected on blood tests after weeks of exposure; and among the effects described outside the trials the commonest is a marked fall in testosterone in men within the first weeks.
Why does the human evidence on what is RAD 140 come from a breast-cancer trial? RAD140 is an investigational selective androgen receptor modulator (SARM) acting on the androgen receptor, the receptor protein inside cells that mediates the effects of androgens, and it was tested in humans under the name vosilasarm, in postmenopausal women with advanced breast cancer. From that trial and the published case, this article sets out which blood markers were recorded, and from the descriptions outside the trials what is said of panels drawn before, during and after exposure.
Liver enzymes and bilirubin in the breast-cancer trial
A liver panel has three values the first human trial of RAD140 speaks to, and the trial tells how often each moved, not by how much. The chart below gives, for the 22 participants: the share with a raised aspartate aminotransferase (AST, a liver enzyme measured in serum), the largest; the share with a raised alanine aminotransferase (ALT); and the share with a raised total bilirubin (conjugated and unconjugated together), the smallest. All of them come from the trial’s list of treatment-emergent adverse events above 10% in frequency, events arising or worsening during treatment whatever their cause.
[Figure 1. Liver and phosphate events in RAD140’s trial. Share of the 22 women with metastatic breast cancer in the phase 1 trial of RAD140 with each blood-test adverse event, at any grade and at grade 3 or 4, all doses pooled; events counted whatever their cause, and the summary gives no peak values.]
Peak values and a breakdown by dose are absent from the published summary, so whether the rises tracked the dose cannot be told. The RAD 140 study was a phase 1 trial (the first stage of testing in humans) run as a dose escalation in heavily pretreated postmenopausal women with ER+/HER2- metastatic breast cancer (oestrogen receptor-positive, HER2-negative breast cancer that has spread).
One more routine panel value moved in that trial: serum phosphate. Grade 3/4 adverse events (severe or life-threatening) occurred in 72.7% of participants across the three once-daily RAD140 dose levels (50 mg in six participants, 100 mg in 13 and 150 mg in three, of which 100 mg a day was set as the maximum tolerated dose, the highest without unacceptable toxicity). Among them stood rises in AST and ALT and hypophosphataemia, an abnormally low blood phosphate, which the chart shows at the same share as those enzyme rises.
Events judged related to treatment were recorded at any grade in 77.3% of participants, at grade 3 in 31.8% and at grade 4 in none, and all of these frequencies describe heavily pretreated patients with metastatic breast cancer rather than healthy adults.
What such a panel looks like in a real injury, a cholestatic pattern with bilirubin far above the range in a young man after weeks of exposure, is set out under RAD140 and the liver.
Why SHBG fell in every trial participant measured
SHBG fell in all 18 participants in whom the protein was measured, and the investigators read the fall not as a harm but as proof that RAD140 had engaged the androgen receptor; the reading cannot be carried across to men, because the participants were women with metastatic breast cancer, and the published summary gives the direction and frequency of the change but not its size.
[Figure 2. Three readings of receptor engagement in the trial. In the phase 1 trial in women with metastatic breast cancer, SHBG fell in 18 of 18 measured and PSA rose in 16 of 20, while paired tumour biopsies showed engagement; neither marker was measured in all 22 enrolled.]
On any blood panel the protein matters because it binds circulating testosterone and governs how much of it circulates unbound, which gives two measures, total testosterone (the whole circulating amount) and free testosterone (the unbound fraction), and any link between RAD 140 and testosterone levels is read through both. PSA (prostate-specific antigen), made under androgen signalling, rose in 16 of 20 and was read as the second surrogate marker, a laboratory value standing in for a target effect; the two denominators differ from each other and from the 22 enrolled, so neither marker was measured in everyone, and paired tumour biopsies taken at baseline and during treatment showed the same engagement in tissue.
What does a very low SHBG on RAD140 mean?
Accounts outside the published studies describe a very low SHBG as an expected finding of exposure to RAD 140, usually reached within the first weeks, and mostly as a sign that the compound is acting rather than a harm in its own right; the value falls far below the laboratory’s reference range (the span found in a healthy reference population) and sits beside a marked fall in total testosterone.
A clinician remarking on the low reading has also been described, and so has a climb back towards the earlier value after exposure ended, while whether so low a reading warrants concern stays an open question in those accounts, turning on the SHBG figure read together with total testosterone, luteinising hormone (LH) and follicle-stimulating hormone (FSH), which are the pituitary hormones that govern testicular function, rather than alone.
Do liver enzymes go back to normal after RAD140 is stopped?
Beyond the trial data, liver enzymes raised during exposure to a compound such as RAD140 are described as returning towards the reference range once exposure ends; drug-induced liver injury of that kind is called self-limiting, because liver tissue renews its cell population, and the recovery is put at weeks to a few months.
A cholestatic pattern is generally described as settling more slowly than a hepatocellular one, and the cholestatic injury in the published case did resolve after the product was withdrawn, in line with the general account; recovery is not held to be universal, and liver enzyme values that stay deranged or worsen after exposure has ended are regarded as needing clinical assessment.
Which blood tests make up a baseline panel before RAD140?
Among the effects described outside the trials, a baseline panel drawn before exposure to RAD140 is generally held to cover the organ systems SARMs are known to affect, beginning with the sex-hormone markers at the head of the list below, among them oestradiol (the main circulating oestrogen).
A lipid profile has also been described as a common inclusion, reporting cholesterol carried by high-density lipoprotein (HDL) and by low-density lipoprotein (LDL), and triglycerides; it belongs among blood tests on SARMs because of the documented fall in HDL cholesterol with the SARM class, and liver function tests belong there because drug-induced liver injury is documented with the class.
Beyond the trial data, a full blood count and creatinine complete the core of the panel, to which some panels add HbA1c (a measure of average blood glucose over the preceding months) and hs-CRP (high-sensitivity C-reactive protein), a sensitive blood marker of inflammation.
In descriptions beyond the trials, prolactin and a thyroid profile are sometimes included as well; no formal standard exists for an unapproved compound, so the panels vary in their make-up.
total and free testosterone
LH and FSH
SHBG
oestradiol
a lipid profile: HDL and LDL cholesterol, the cholesterol carried by the two main lipoproteins, and triglycerides
liver function tests, which report the aminotransferases and bilirubin
a full blood count, the tally of red cells, white cells and platelets, with its haematocrit giving the share of blood volume made up of red cells
creatinine, a waste product cleared by renal filtration, as the usual measure of renal function
in some panels, HbA1c
in some panels, hs-CRP
sometimes, prolactin, the pituitary hormone that drives lactation
sometimes, a thyroid profile, which pairs thyroid-stimulating hormone with the circulating thyroid hormones
Which baseline results mean you should not start a cycle?
Outside the published trials, three baseline results are described as grounds for not beginning exposure, a total testosterone already below the laboratory’s reference range, an already raised cholesterol and an abnormal prolactin, and since no threshold is stated, the judgement in such accounts rests on the starting value itself.
A clinician prescribing testosterone gel after a low pre-exposure reading has also been described in a few accounts, and a clinician proposing testosterone therapy after a low free testosterone in another, a case in which any later exposure would combine RAD 140 and TRT; apparently low baseline readings in men in their late teens or twenties appear in those accounts too, with the question whether such values are normal for that age, and for them no agreed figure exists.
Does RAD140 lower testosterone, LH and FSH, and do they come back?
In descriptions beyond the trials, RAD140 lowers endogenous testosterone together with LH and FSH, a fall shared by other compounds acting on the androgen receptor. RAD 140 suppression of this kind arises through feedback, an androgenic signal reaching the hypothalamus and the pituitary and suppressing the release of LH and FSH, which fall first, with total testosterone following within weeks of continuous exposure.
Recovery of all three hormones from that suppressed state has also been described as the usual course: once exposure ends LH and FSH rise again, total testosterone returns over weeks to several months, the extent and pace of the return vary with the length and intensity of exposure and with the starting value, and prolonged suppression is the exception rather than the rule. No agreed time course exists for RAD140, so the course in any one case is established only through repeat measurement.
Cholesterol, thyroid, prolactin and other changes described in discussions
Beyond the trial data, the changes in blood values described are set out in the list below, with lipid markers back within range when retested months later in some accounts. Two of the changes concern the growth hormone secretagogue MK-677 (ibutamoren) and vitamin D; one account describes the lipid profile as worse than that seen with an injectable anabolic-androgenic steroid, and another sets triglyceride values before exposure beside those after it.
lipid markers slightly raised at the end of exposure, in some accounts
thyroid values shifting, in a few accounts
a raised prolactin after combined exposure to RAD140 and MK-677
a low morning blood glucose
a low concentration of vitamin D after exposure
In descriptions beyond the trials, cramps, a reduced tolerance of alcohol and palpitations that alarmed a relative also appear after exposure, each described only once or twice and none tied to a measured value.
How long do cholesterol and HDL take to recover after the cycle?
Total and HDL cholesterol are generally held to return towards their earlier values within several weeks to a few months of the end of exposure, HDL cholesterol being the slowest of the lipid fractions to recover, on a time course that depends on the compound, on the length of exposure and on the starting lipid profile; no agreed interval exists, so only repeat measurement establishes the direction of change in any one case, and a lipid profile still deranged after that span is regarded as calling for clinical review.
Which test results show you are suppressed or should stop the cycle?
The results that mark suppression of endogenous testosterone are described, in accounts outside the published studies, as a combination of hormone readings, set out in the list below together with the results given as grounds for ending exposure, and the combination is read against the earlier baseline rather than against the range alone, so a fall that stays inside the range is read differently from one that drops beneath it.
for suppression, a total testosterone below the laboratory’s reference range
for suppression, LH at or near the lower limit of its reference range
for suppression, FSH at or near the lower limit of its reference range
as grounds for ending exposure, liver enzymes well above the reference range
as grounds for ending exposure, discomfort over the right upper abdomen together with those raised liver enzymes
A few of those accounts describe a clinician advising an end to exposure and a repeat of the tests and a physical examination some months later, and a clinician asking that every compound be stopped before any blood was drawn, with the question whether a panel drawn at that point still shows any change; no numerical cut-off is settled across them, because the same figures are read differently according to the markers measured beside them.
How long RAD140 stays in the blood after the last dose
A blood draw in the first days after the last dose is taken under continuing exposure, because of how slowly the compound clears. The RAD 140 half life measured in the first human trial, in postmenopausal women with metastatic breast cancer given testolone orally once daily, was an elimination half-life (the time its blood concentration takes to fall by half) of 44.7 hours, and on that figure the investigators judged once-daily administration of the SARM RAD140 to be supported.
A compound that clears so slowly is still circulating when blood is drawn in the first days after the last dose, so the hormone and liver function values from an early draw are measured under continuing exposure rather than after its end.
When to get bloods after RAD-140 cycle?
The timing of a blood draw after exposure to RAD-140 ends is described, outside the trial record, as unsettled, accounts dividing three ways on the draw after exposure, one of them placing it after post-cycle therapy for SARMs, the course of selective oestrogen receptor modulators that follows exposure, with further draws described besides, as the list below sets out.
within the first days after the last dose, in some accounts
after a longer wait, on the grounds that the long elimination half-life makes an early panel a measure of the compound’s presence rather than its aftermath
after the end of post-cycle therapy
partway through exposure, as a means of checking liver function and the extent of the hormone fall
repeat draws, in many accounts, each series continuing until the readings match the earlier baseline
In those accounts the baseline counts for more than any single interval where repeat draws are described, and in a few of the accounts describing draws partway through exposure a clinician ordered the mid-exposure tests.
Accounts outside the published studies describe the final draw as paired with a body composition scan and photographs, the blood panel read together with a RAD 140 before and after comparison of body composition, and no interval is agreed in any of them.
Why the contents of a product change what blood tests show
The contents of a product change what blood tests show because the Therapeutic Goods Administration (TGA), Australia’s medicines regulator, tested unapproved selective androgen receptor modulator products and found them significantly under-dosed. A blood value measured after exposure to a product sold as RAD140 but not legit RAD 140 may reflect less of the compound than the label states, so an unchanged liver or hormone value cannot by itself be read as the compound’s own effect at the stated dose; the TGA alert gives the direction of the shortfall but no figure for its size.
That shortfall is why the RAD-140 for sale in the shop, like every compound in its range of UK SARMs, is supplied for laboratory research with batch and purity data, the analytical record of each production lot.
Limits of the evidence on RAD140 blood tests
Human evidence on RAD 140 blood work is thin, and its limits run in one direction. The single human trial enrolled the heavily pretreated women with metastatic breast cancer counted in the table below, so the frequencies it recorded for raised liver enzymes and a falling SHBG cannot be assumed to carry over to healthy men, and for drug-induced liver injury the evidence rests on one published case report and on a LiverTox monograph covering the SARM class as a whole.
The TGA’s testing of products shows that a label and a product’s contents may diverge, which weakens any inference from a measured value back to a stated dose, and weaker still are the descriptions outside the published trials, each single and unverified, many involving exposure to other compounds alongside testolone.
What each source shows about RAD140 blood tests
Source
Who or what was studied
Blood-test finding
Limit
Phase 1 trial (2022)
22 heavily pretreated postmenopausal women with ER+/HER2- metastatic breast cancer
Raised AST in 59.1%, ALT in 45.5% and bilirubin in 27.3%; SHBG fell in 18 of 18 measured
Cancer patients; frequencies only, no peak values
Case report (2022)
One 24-year-old man after five weeks of a product sold as RAD-140
Cholestatic liver injury, total bilirubin peaking at 38.5 mg/dL; resolved after stopping
A single case
LiverTox monograph
The SARM class as a whole
SARMs associated with a cholestatic pattern of liver injury
Not specific to RAD140
TGA safety alert
Unapproved SARM products on the Australian market
Products found significantly under-dosed
No figure for the size of the shortfall; one market
Several further changes are known only from descriptions outside the published trials: falls in testosterone, LH and FSH in men, changes in total and HDL cholesterol, and shifts in thyroid values, prolactin and blood glucose. No published study among this article’s sources has measured any of them.
Important information. This article summarises published research and case reports, and notes where effects are described outside the published trials. It is not medical advice, and Max Muscle Labs does not give dosing guidance or any information implying human use. Many of the compounds discussed here are not approved for human use by the MHRA, the FDA or any other regulator, and many are prohibited in sport by WADA. Products sold by Max Muscle Labs are supplied strictly for laboratory and analytical research use and are not for human or veterinary consumption.
Check what you remember
4 questions on this article; the right answer is marked.
In the breast-cancer trial, how did the investigators read the fall in SHBG seen in every participant measured?
As a sign that RAD140 had engaged the androgen receptor ✓
As an early warning of drug-induced injury to the liver
As an effect of the cancer rather than of RAD140
As a sign that circulating oestradiol had risen sharply
SHBG fell in all 18 participants measured, and the investigators read it, alongside PSA, as a surrogate marker that the compound had engaged the androgen receptor.
Which blood finding was the most frequent adverse event in the first human trial of RAD140?
A raised aspartate aminotransferase (AST) ✓
A raised alanine aminotransferase (ALT)
A raised total blood bilirubin
An abnormally low phosphate in the blood serum
A raised AST was recorded in 59.1% of the 22 participants, ahead of ALT at 45.5% and total bilirubin at 27.3%.
What pattern of liver injury did the published case report describe in a man exposed to a product sold as RAD-140?
A cholestatic injury that resolved once exposure ended ✓
A hepatocellular injury that resolved once exposure ended
A cholestatic injury that left lasting liver damage
A hepatocellular injury that needed a liver transplant
The 24-year-old man had a cholestatic liver injury with bilirubin peaking at 38.5 mg/dL, and both the injury and his symptoms resolved after he stopped the product.
Why does the 44.7-hour half-life of RAD140 matter for a blood draw in the first days after exposure ends?
The compound still circulates, so the panel reflects ongoing exposure ✓
The compound has already cleared, so the panel reflects full recovery
The compound binds SHBG, so the panel overstates free testosterone
The compound raises bilirubin, so the panel misreads the liver enzyme values
With a half-life of 44.7 hours, RAD140 is still in the blood for days after exposure ends, so an early panel measures its presence rather than its aftermath.
Specialty Registrar in Chemical Pathology and Metabolic Medicine
Matthew Waite is a specialty registrar in chemical pathology and metabolic medicine at Imperial College Healthcare NHS Trust. Matthew specialises in cardiology and lipidology.
Specialty Registrar in Endocrinology and Diabetes; Clinical Research Fellow
Elizabeth Hyams is a specialty registrar in endocrinology and diabetes and a clinical research fellow in the Reproductive Endocrinology group at Imperial College London. Elizabeth specialises in endocrinology and the hypothalamic-pituitary-gonadal axis.
Is RAD140 liver toxic: raised liver enzymes were the most frequent adverse event in its only human trial, and case reports describe cholestatic jaundice.
Is RAD-140 bad for kidneys: no direct kidney harm has been shown, but one case report records acute kidney injury during severe drug-induced liver injury.
RAD 140 blood work: the markers and what the evidence shows
By Matthew Waite, MB BChir · Reviewed by Elizabeth Hyams
Published · 17 min read
RAD 140 blood work in brief
Two parts of a blood panel carry the evidence on RAD 140 blood work: the liver tests and the sex-hormone panel. In the one human trial, in women with advanced breast cancer, many participants showed raised liver enzymes (the aminotransferases released from injured liver tissue) and raised bilirubin, the bile pigment that liver tissue clears from blood.
In the same trial, sex hormone-binding globulin (SHBG, the main carrier protein for testosterone in blood) fell in every participant with a measured value; a published case report from outside the trial describes a severe drug-induced liver injury detected on blood tests after weeks of exposure; and among the effects described outside the trials the commonest is a marked fall in testosterone in men within the first weeks.
Why does the human evidence on what is RAD 140 come from a breast-cancer trial? RAD140 is an investigational selective androgen receptor modulator (SARM) acting on the androgen receptor, the receptor protein inside cells that mediates the effects of androgens, and it was tested in humans under the name vosilasarm, in postmenopausal women with advanced breast cancer. From that trial and the published case, this article sets out which blood markers were recorded, and from the descriptions outside the trials what is said of panels drawn before, during and after exposure.
Liver enzymes and bilirubin in the breast-cancer trial
A liver panel has three values the first human trial of RAD140 speaks to, and the trial tells how often each moved, not by how much. The chart below gives, for the 22 participants: the share with a raised aspartate aminotransferase (AST, a liver enzyme measured in serum), the largest; the share with a raised alanine aminotransferase (ALT); and the share with a raised total bilirubin (conjugated and unconjugated together), the smallest. All of them come from the trial’s list of treatment-emergent adverse events above 10% in frequency, events arising or worsening during treatment whatever their cause.
Peak values and a breakdown by dose are absent from the published summary, so whether the rises tracked the dose cannot be told. The RAD 140 study was a phase 1 trial (the first stage of testing in humans) run as a dose escalation in heavily pretreated postmenopausal women with ER+/HER2- metastatic breast cancer (oestrogen receptor-positive, HER2-negative breast cancer that has spread).
One more routine panel value moved in that trial: serum phosphate. Grade 3/4 adverse events (severe or life-threatening) occurred in 72.7% of participants across the three once-daily RAD140 dose levels (50 mg in six participants, 100 mg in 13 and 150 mg in three, of which 100 mg a day was set as the maximum tolerated dose, the highest without unacceptable toxicity). Among them stood rises in AST and ALT and hypophosphataemia, an abnormally low blood phosphate, which the chart shows at the same share as those enzyme rises.
Events judged related to treatment were recorded at any grade in 77.3% of participants, at grade 3 in 31.8% and at grade 4 in none, and all of these frequencies describe heavily pretreated patients with metastatic breast cancer rather than healthy adults.
What such a panel looks like in a real injury, a cholestatic pattern with bilirubin far above the range in a young man after weeks of exposure, is set out under RAD140 and the liver.
Why SHBG fell in every trial participant measured
SHBG fell in all 18 participants in whom the protein was measured, and the investigators read the fall not as a harm but as proof that RAD140 had engaged the androgen receptor; the reading cannot be carried across to men, because the participants were women with metastatic breast cancer, and the published summary gives the direction and frequency of the change but not its size.
On any blood panel the protein matters because it binds circulating testosterone and governs how much of it circulates unbound, which gives two measures, total testosterone (the whole circulating amount) and free testosterone (the unbound fraction), and any link between RAD 140 and testosterone levels is read through both. PSA (prostate-specific antigen), made under androgen signalling, rose in 16 of 20 and was read as the second surrogate marker, a laboratory value standing in for a target effect; the two denominators differ from each other and from the 22 enrolled, so neither marker was measured in everyone, and paired tumour biopsies taken at baseline and during treatment showed the same engagement in tissue.
What does a very low SHBG on RAD140 mean?
Accounts outside the published studies describe a very low SHBG as an expected finding of exposure to RAD 140, usually reached within the first weeks, and mostly as a sign that the compound is acting rather than a harm in its own right; the value falls far below the laboratory’s reference range (the span found in a healthy reference population) and sits beside a marked fall in total testosterone.
A clinician remarking on the low reading has also been described, and so has a climb back towards the earlier value after exposure ended, while whether so low a reading warrants concern stays an open question in those accounts, turning on the SHBG figure read together with total testosterone, luteinising hormone (LH) and follicle-stimulating hormone (FSH), which are the pituitary hormones that govern testicular function, rather than alone.
Do liver enzymes go back to normal after RAD140 is stopped?
Beyond the trial data, liver enzymes raised during exposure to a compound such as RAD140 are described as returning towards the reference range once exposure ends; drug-induced liver injury of that kind is called self-limiting, because liver tissue renews its cell population, and the recovery is put at weeks to a few months.
A cholestatic pattern is generally described as settling more slowly than a hepatocellular one, and the cholestatic injury in the published case did resolve after the product was withdrawn, in line with the general account; recovery is not held to be universal, and liver enzyme values that stay deranged or worsen after exposure has ended are regarded as needing clinical assessment.
Which blood tests make up a baseline panel before RAD140?
Among the effects described outside the trials, a baseline panel drawn before exposure to RAD140 is generally held to cover the organ systems SARMs are known to affect, beginning with the sex-hormone markers at the head of the list below, among them oestradiol (the main circulating oestrogen).
A lipid profile has also been described as a common inclusion, reporting cholesterol carried by high-density lipoprotein (HDL) and by low-density lipoprotein (LDL), and triglycerides; it belongs among blood tests on SARMs because of the documented fall in HDL cholesterol with the SARM class, and liver function tests belong there because drug-induced liver injury is documented with the class.
Beyond the trial data, a full blood count and creatinine complete the core of the panel, to which some panels add HbA1c (a measure of average blood glucose over the preceding months) and hs-CRP (high-sensitivity C-reactive protein), a sensitive blood marker of inflammation.
In descriptions beyond the trials, prolactin and a thyroid profile are sometimes included as well; no formal standard exists for an unapproved compound, so the panels vary in their make-up.
Which baseline results mean you should not start a cycle?
Outside the published trials, three baseline results are described as grounds for not beginning exposure, a total testosterone already below the laboratory’s reference range, an already raised cholesterol and an abnormal prolactin, and since no threshold is stated, the judgement in such accounts rests on the starting value itself.
A clinician prescribing testosterone gel after a low pre-exposure reading has also been described in a few accounts, and a clinician proposing testosterone therapy after a low free testosterone in another, a case in which any later exposure would combine RAD 140 and TRT; apparently low baseline readings in men in their late teens or twenties appear in those accounts too, with the question whether such values are normal for that age, and for them no agreed figure exists.
Does RAD140 lower testosterone, LH and FSH, and do they come back?
In descriptions beyond the trials, RAD140 lowers endogenous testosterone together with LH and FSH, a fall shared by other compounds acting on the androgen receptor. RAD 140 suppression of this kind arises through feedback, an androgenic signal reaching the hypothalamus and the pituitary and suppressing the release of LH and FSH, which fall first, with total testosterone following within weeks of continuous exposure.
Recovery of all three hormones from that suppressed state has also been described as the usual course: once exposure ends LH and FSH rise again, total testosterone returns over weeks to several months, the extent and pace of the return vary with the length and intensity of exposure and with the starting value, and prolonged suppression is the exception rather than the rule. No agreed time course exists for RAD140, so the course in any one case is established only through repeat measurement.
Cholesterol, thyroid, prolactin and other changes described in discussions
Beyond the trial data, the changes in blood values described are set out in the list below, with lipid markers back within range when retested months later in some accounts. Two of the changes concern the growth hormone secretagogue MK-677 (ibutamoren) and vitamin D; one account describes the lipid profile as worse than that seen with an injectable anabolic-androgenic steroid, and another sets triglyceride values before exposure beside those after it.
In descriptions beyond the trials, cramps, a reduced tolerance of alcohol and palpitations that alarmed a relative also appear after exposure, each described only once or twice and none tied to a measured value.
How long do cholesterol and HDL take to recover after the cycle?
Total and HDL cholesterol are generally held to return towards their earlier values within several weeks to a few months of the end of exposure, HDL cholesterol being the slowest of the lipid fractions to recover, on a time course that depends on the compound, on the length of exposure and on the starting lipid profile; no agreed interval exists, so only repeat measurement establishes the direction of change in any one case, and a lipid profile still deranged after that span is regarded as calling for clinical review.
Which test results show you are suppressed or should stop the cycle?
The results that mark suppression of endogenous testosterone are described, in accounts outside the published studies, as a combination of hormone readings, set out in the list below together with the results given as grounds for ending exposure, and the combination is read against the earlier baseline rather than against the range alone, so a fall that stays inside the range is read differently from one that drops beneath it.
A few of those accounts describe a clinician advising an end to exposure and a repeat of the tests and a physical examination some months later, and a clinician asking that every compound be stopped before any blood was drawn, with the question whether a panel drawn at that point still shows any change; no numerical cut-off is settled across them, because the same figures are read differently according to the markers measured beside them.
How long RAD140 stays in the blood after the last dose
A blood draw in the first days after the last dose is taken under continuing exposure, because of how slowly the compound clears. The RAD 140 half life measured in the first human trial, in postmenopausal women with metastatic breast cancer given testolone orally once daily, was an elimination half-life (the time its blood concentration takes to fall by half) of 44.7 hours, and on that figure the investigators judged once-daily administration of the SARM RAD140 to be supported.
A compound that clears so slowly is still circulating when blood is drawn in the first days after the last dose, so the hormone and liver function values from an early draw are measured under continuing exposure rather than after its end.
When to get bloods after RAD-140 cycle?
The timing of a blood draw after exposure to RAD-140 ends is described, outside the trial record, as unsettled, accounts dividing three ways on the draw after exposure, one of them placing it after post-cycle therapy for SARMs, the course of selective oestrogen receptor modulators that follows exposure, with further draws described besides, as the list below sets out.
In those accounts the baseline counts for more than any single interval where repeat draws are described, and in a few of the accounts describing draws partway through exposure a clinician ordered the mid-exposure tests.
Accounts outside the published studies describe the final draw as paired with a body composition scan and photographs, the blood panel read together with a RAD 140 before and after comparison of body composition, and no interval is agreed in any of them.
Why the contents of a product change what blood tests show
The contents of a product change what blood tests show because the Therapeutic Goods Administration (TGA), Australia’s medicines regulator, tested unapproved selective androgen receptor modulator products and found them significantly under-dosed. A blood value measured after exposure to a product sold as RAD140 but not legit RAD 140 may reflect less of the compound than the label states, so an unchanged liver or hormone value cannot by itself be read as the compound’s own effect at the stated dose; the TGA alert gives the direction of the shortfall but no figure for its size.
That shortfall is why the RAD-140 for sale in the shop, like every compound in its range of UK SARMs, is supplied for laboratory research with batch and purity data, the analytical record of each production lot.
Limits of the evidence on RAD140 blood tests
Human evidence on RAD 140 blood work is thin, and its limits run in one direction. The single human trial enrolled the heavily pretreated women with metastatic breast cancer counted in the table below, so the frequencies it recorded for raised liver enzymes and a falling SHBG cannot be assumed to carry over to healthy men, and for drug-induced liver injury the evidence rests on one published case report and on a LiverTox monograph covering the SARM class as a whole.
The TGA’s testing of products shows that a label and a product’s contents may diverge, which weakens any inference from a measured value back to a stated dose, and weaker still are the descriptions outside the published trials, each single and unverified, many involving exposure to other compounds alongside testolone.
What each source shows about RAD140 blood tests
Several further changes are known only from descriptions outside the published trials: falls in testosterone, LH and FSH in men, changes in total and HDL cholesterol, and shifts in thyroid values, prolactin and blood glucose. No published study among this article’s sources has measured any of them.
Check what you remember
4 questions on this article; the right answer is marked.
SHBG fell in all 18 participants measured, and the investigators read it, alongside PSA, as a surrogate marker that the compound had engaged the androgen receptor.
A raised AST was recorded in 59.1% of the 22 participants, ahead of ALT at 45.5% and total bilirubin at 27.3%.
The 24-year-old man had a cholestatic liver injury with bilirubin peaking at 38.5 mg/dL, and both the injury and his symptoms resolved after he stopped the product.
With a half-life of 44.7 hours, RAD140 is still in the blood for days after exposure ends, so an early panel measures its presence rather than its aftermath.
Matthew Waite, MB BChir · Imperial College Healthcare
Specialty Registrar in Chemical Pathology and Metabolic Medicine
Matthew Waite is a specialty registrar in chemical pathology and metabolic medicine at Imperial College Healthcare NHS Trust. Matthew specialises in cardiology and lipidology.
Elizabeth Hyams · Imperial College London · Last reviewed
Specialty Registrar in Endocrinology and Diabetes; Clinical Research Fellow
Elizabeth Hyams is a specialty registrar in endocrinology and diabetes and a clinical research fellow in the Reproductive Endocrinology group at Imperial College London. Elizabeth specialises in endocrinology and the hypothalamic-pituitary-gonadal axis.
Related Posts
Is RAD140 liver toxic? What trials and case reports show
Is RAD140 liver toxic: raised liver enzymes were the most frequent adverse event in its only human trial, and case reports describe cholestatic jaundice.
RAD 140 teenager: what a case report and animal data show
RAD 140 teenager evidence records harm: myopericarditis in a 16-year-old boy after his first dose, and raised frailty and mortality risk in mice.
Is RAD-140 bad for kidneys? What the case reports show
Is RAD-140 bad for kidneys: no direct kidney harm has been shown, but one case report records acute kidney injury during severe drug-induced liver injury.
How bad is RAD-140 for the heart? What the evidence shows
How bad is RAD-140 for the heart remains unmeasured in published studies, while case reports describe myocarditis and heart failure after exposure.